Berberol
Berberol, licence 80141205: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- BerEva, BerolEva, CardioBerol, CholesBerol, EvaBerol, EvaChol
- Licence holder
- Evascience Inc.
- NPN or DIN-HM
- 80141205
- Status
- Active licence
- Licence date
- 22 May 2025
- Revision date
- 30 July 2025
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Berberis aristata Source : Berberis aristata - Écorce de tige Potency : 85.0 % Berberine | 588.0 mg | Not calculated |
| Silybum marianum Source : Silybum marianum - Graine Extract : Matériel brut sec Extraction ratio : 25:1 Dry plant equivalent : 2625 mg Potency : 45.0 % Silymarin | 105.0 mg | Not calculated |
| Silybum marianum Source : Silybum marianum - Fruit Extract : Matériel brut sec Extraction ratio : 25:1 Dry plant equivalent : 2625 mg Potency : 45.0 % Silymarin | 105.0 mg | Not calculated |
Non-medicinal ingredients
Cellulose microcristalline, Phosphate de calcium dibasique, Saveur de vanille, Croscarmellose de sodium, Gomme-laque, Vanilline, Esters d'acide acétique de mono et diglycérides, Hypromellose, Sels de magnésium d'acides gras, Dioxyde de silicium, Amidon prégélatinisé
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 18.0 ans | 1.0 Comprimé | 2.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Berberol, taken alone or as a complementary therapy, helps to support/maintain lipid parameters (total cholesterol, LDL-cholesterol, triglycerides) and support/maintain blood glucose levels, promoting cardiovascular health. Berberol helps to improve the cardiovascular health. Berberol helps to support the metabolism of lipids and glucose. Berberol helps in the maintenance of healthy cholesterol and sugar blood levels. Berberol is an effective complement therapy for the treatment of high cholesterol. Berberol contributes to the maintenance of normal blood cholesterol levels. Berberol helps to promote cardiometabolic health. Berberol helps to promote cardiovascular health. Berberol helps to support/maintain the lipid and glucose profile by maintaining total cholesterol, LDL-cholesterol, triglycerides and blood glucose levels.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80141205
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Has the product changed? Photograph the packaging.